Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. David Taylor

Representative David Taylor (Republican-Ohio) recently sold shares of Eli Lilly and Company (NYSE:LLY). In a filing disclosed on February 20th, the Representative disclosed that they had sold between $1,001 and $15,000 in Eli Lilly and Company stock on February 9th. The trade occurred in the Representative’s “DAVID TAYLOR TRUST > SCHWAB JOINT BROKERAGE #1 (HOME GROWN)” account.

Representative David Taylor also recently made the following trade(s):

• Purchased $1,001 – $15,000 in shares of Progressive (NYSE:PGR) on 2/10/2026.
• Sold $1,001 – $15,000 in shares of Parker-Hannifin (NYSE:PH) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Visa (NYSE:V) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Procter & Gamble (NYSE:PG) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Amazon.com (NASDAQ:AMZN) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 2/9/2026.
• Purchased $1,001 – $15,000 in shares of Microsoft (NASDAQ:MSFT) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Broadcom (NASDAQ:AVGO) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Amgen (NASDAQ:AMGN) on 1/29/2026.

Eli Lilly and Company Trading Down 0.5%

LLY traded down $5.16 during trading hours on Tuesday, reaching $1,053.40. 919,715 shares of the company’s stock traded hands, compared to its average volume of 3,337,790. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a 50-day moving average price of $1,054.73 and a 200 day moving average price of $920.78. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,133.95. The firm has a market capitalization of $993.74 billion, a PE ratio of 45.80, a PEG ratio of 1.17 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping analysts’ consensus estimates of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The firm had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. During the same period in the prior year, the business posted $5.32 earnings per share. The business’s revenue for the quarter was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.7%. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. Eli Lilly and Company’s dividend payout ratio is 30.15%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Novo Nordisk’s CagriSema missed non‑inferiority versus Lilly’s tirzepatide in an 84‑week head‑to‑head, a clear competitive win for Lilly that pushed investor expectations for longer‑term demand and market share for Zepbound. Novo’s stumbles burnish Lilly’s widening lead in weight-loss drugs (Reuters)
• Positive Sentiment: The FDA approved a multi‑dose KwikPen for Zepbound, and Lilly launched the month‑long pen option—improving convenience, lowering device churn, and reinforcing adherence/retention economics for its obesity franchise. Eli Lilly’s Zepbound Gets FDA OK for Multi‑Dose Pen (WSJ)
• Positive Sentiment: Lilly confirmed commercial availability and self‑pay pricing/access options for the KwikPen (company release), which helps preserve patient affordability and adoption momentum. Zepbound now available in multi‑dose KwikPen (PR Newswire)
• Positive Sentiment: Goldman Sachs maintained its Buy rating and high price target on LLY, citing a conservative 2026 guide but a diversified pipeline and capital flexibility—supporting analyst confidence and upside expectations. Goldman Sachs maintains Buy on Eli Lilly (TipRanks)
• Positive Sentiment: New clinical data and licensing/combination trial results (e.g., Taltz + Zepbound in psoriasis patients with obesity) broaden Lilly’s pipeline utility and cross‑sell opportunities. Lilly expands pipeline with positive trial data (InsiderMonkey)
• Positive Sentiment: Hedge funds and institutional flows have been heavy into mega‑caps including Lilly, supporting liquidity and demand at current levels. Hedge funds buy Eli Lilly (Benzinga)
• Neutral Sentiment: Some analysts note LLY has recently trailed the S&P 500 on a short‑term basis, a reminder that valuation and broader market cycles can pressure performance even amid favorable fundamentals. Is Eli Lilly Stock Underperforming the S&P 500? (Barchart)
• Negative Sentiment: Large insider and institutional sell activity (documented in recent trading/holdings reports) can be perceived negatively by some investors and may add short‑term pressure if sustained. Eli Lilly rises as rival trial data strengthen tirzepatide’s edge (QuiverQuant)

Institutional Investors Weigh In On Eli Lilly and Company

Several institutional investors have recently bought and sold shares of the company. Norges Bank purchased a new position in Eli Lilly and Company during the fourth quarter worth about $12,976,634,000. Laurel Wealth Advisors LLC lifted its holdings in Eli Lilly and Company by 78,621.2% during the 2nd quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock worth $9,005,392,000 after buying an additional 11,537,661 shares during the last quarter. Capital Research Global Investors boosted its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after acquiring an additional 4,332,008 shares in the last quarter. J. Stern & Co. LLP increased its holdings in shares of Eli Lilly and Company by 46,191.3% in the 4th quarter. J. Stern & Co. LLP now owns 4,047,245 shares of the company’s stock valued at $4,047,245,000 after acquiring an additional 4,038,502 shares during the last quarter. Finally, Cardano Risk Management B.V. lifted its stake in Eli Lilly and Company by 876.1% during the fourth quarter. Cardano Risk Management B.V. now owns 2,375,050 shares of the company’s stock worth $2,552,419,000 after purchasing an additional 2,131,734 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on LLY shares. Daiwa Securities Group increased their target price on shares of Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a research report on Wednesday, February 18th. National Bank Financial set a $1,286.00 price target on Eli Lilly and Company in a research report on Monday, December 1st. Barclays started coverage on Eli Lilly and Company in a report on Thursday. They issued an “overweight” rating and a $1,350.00 price objective for the company. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the company an “overweight” rating in a research report on Thursday, February 5th. Finally, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $1,228.54.

About Representative Taylor

David Taylor (Republican Party) is a member of the U.S. House, representing Ohio’s 2nd Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Taylor (Republican Party) ran for election to the U.S. House to represent Ohio’s 2nd Congressional District. He won in the general election on November 5, 2024.

David Taylor graduated from Amelia High School. Taylor earned degrees from Miami University (Ohio) and the University of Dayton School of Law. Taylor’s career experience includes working as an attorney and as a businessman at Sardinia Ready Mix, Inc.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.